Iboga is the root bark of the Tabernanthe Iboga plant, which grows in the rain forests of Equatorial Africa. The name of the plant “Taber Ibo” literally means “breaking open the head.” Iboga leads you into your subconscious mind. The insights can be used to let old patterns and/or habits go. The ego is inferior. You can take a look at those moments in your life where you have made certain choices that now do not serve you anymore, choices that you want to change.

Iboga is a “plant spirit”, that can help you to break free from many types of addiction, because of the insights you gain from this Spiritual Journey. It is mostly used for spiritual development and personal growth.

Iboga is a sacred plant, that contains a dozen indole alkaloids. One of these alkaloids, C20H26N2O, causes withdrawal symptoms to stay away.

Iboga is an “oneirophrenic” and not a “hallucinogenic”. It is a journey into your past and the visions have a deep symbolic meaning. It is this direct experience that is the basis of your transformation. The silence that you will enter to reconnect with yourself is part of a natural process of the mind. It is a mind-reset.

Iboga comes in waves, each dreamwave gives you new layers of information. Remember that you know the answer to all your questions yourself. It comes from your sub-consciousness. The psychoactive properties result in a dreamlike state that lasts for several hours.

The feeling of “cold turkey” stays away. The body is completely detoxified. The desire for drug use is gone for a period of several weeks, usually several months. After an Iboga ceremony, many users are able to see the problems that underlie the addiction. It is important that you clearly define and identify your intentions and goal(s) in advance. What do you want to change?

We will guide you and you will have the chance to gain insights about yourself. You are the one who makes your dreams come true.


An Iboga ceremony consists of three phases. The first phase is a dream state in which events of the past, thoughts or ideas can be perceived as visual presentations. Every human being is essentially good. The second phase is a period where those experiences will be evaluated. The third phase is a remaining period of stimulation, eventually resulting in sleep. Iboga is an individual experience for everybody.

After the treatment, you may find it difficult to fall asleep easily for a few days. This is because your mind is still processing everything that you have gone through. This is OK! You will automatically go back to your normal biorhythm. You will also find that you can’t eat as usual, in fact, you will eat less for a few days. One interesting story is told that warriors in Africa could stay away from home longer to hunt after taking Iboga

At all times the safety of our participants is our primary concern. Iboga is completely safe when you have passed the necessary pre-medical screening and when used correctly with experienced and responsible practitioners to guide you whilst in a safe and caring environment. We have a 100% safety record.

All the including and excluding criteria have to be considered and the right conditions for the experience need to be created. A full dose of Iboga induces a powerful and long-lasting meditation experience (up to 36 hours). The participant must be in reasonably good health on both a mental and physical level. Each participant needs to provide the results of medical tests showing the condition of their liver and heart. You should never take Iboga on your own, without an experienced and trained provider. 

Precautions and Rules to follow – There are a number of precautions and rules to be followed before, during and after the experience. We make sure all our participants are well informed about all the experience considerations, prior to participating.

Studies suggest that Iboga has potential in the treatment of addiction to several substances.

  • Numerous studies have been published demonstrating the anti-addictive effects of Iboga in animals:
  • 4. Vastag B. Addiction treatment strives for legitimacy. JAMA . 2002;288:3096, 3099.
  • 8. Glick S, Maisonneuve IM, Szumlinski KK. Mechanisms of action of Iboga: relevance to putative therapeutic effects and development of a safer Iboga alkaloid congener. Alkaloids Chem Biol . 2001;56:39-53.

Iboga has a complex mechanism of action (pharmacokinetics) in the brain that is not yet fully understood. What is known is that once consumed, ibogaine quickly stimulates the production of “glial cell line-derived neurotrophic factor” (GDNF) – part of the brain’s support system, which resets the reward circuitry situated in the ventral tegmental area (VTA) of the brain. Put simply, addiction is a brain impairment characterised by a profound disruption in particular neurotransmitter circuits in the brain caused by the abused substance. Iboga resets these neurological pathways and refreshes the central nervous system. 

Put simply, addiction is a brain impairment characterised by a profound disruption in particular neurotransmitter circuits in the brain caused by the abused substance. 

  • Participants report:
  • •  Increased wellness and well-being
  • •  A life-changing experience
  • •  Increased spiritual awareness
  • •  Freedom from addictions – such as sugar/food, smoking, physical, mental and sexual
  • •  Reduced stress, less fear/freedom from fear
  • •  Freedom from old negative patterns and cycles
  • •  Losing weight in the weeks after their experience

The iboga experience comes in waves. During the first wave participants can experience several mild symptoms. These symptoms may include anxiety, muscle spasms, speech changes, nausea (especially from movement) and cardiovascular effects (palpitations). These symptoms are short-lived and lessen as time goes by. You may experience some of those symptoms or none of them. During the retreat there can also be what is called a “grey day” when some people feel tired but sleepless, some are anxious or angry as suppressed emotions continue to rise to the surface. It should be noted that you can also feel elated and at peace with the universe. This is often described as the Satori state. a Japanese Budhist word 

Each member of our staff is trained to the standard required to provide full safety and care to all participants. Every application is vetted with a medical doctor in advance. We always follow Iboga safety protocols before, during and after participation.

The experience takes place over 3 days. Once all participants have arrived we assemble together and each member of the group introduces themselves. We will give an introduction that covers the history of Iboga and gives guidelines about the ceremony so that you will be fully prepared and can get the most out of your experience. It is here that people reflect on their intentions.

We open the ceremony together with a sacred prayer. Over the course of the experience the medicine comes in waves and during the process each participant makes a trip to their past. The visions have a symbolic meaning. This meditative experience is the basis of the transformation. The silence is very important. Iboga is a meditation with a deeply profound effect. The transformation is the natural process of the mind.

At all times you will be monitored by and in the safe care of a highly experienced team. The process contains three stages.

  • • The first phase is 6-10 hours of dream state. Visual presentations or thoughts are observed with events from the past.
  • • The second phase is a period of 10-12 hours in which these events/experiences are evaluated and re-arranged again,
  • • The third stage is a period of sleep.

The perception of Iboga is an individual process for everybody. Each participant is in a high state of vigilance without producing side effects. Sometimes you have visions or you have not. It is important to have no expectations, only intention, as the experience is always different for each participant. Do not worry – Iboga does not condemn and it has no opinion. Iboga is there for you to give you insights and information – it will give you exactly what you need, providing solutions to your worries, problems and concerns in a kind and loving way.

During the process some participants have to vomit, others do not (in our experience very few). It is all good. At all times you will be in the safe care of a highly experienced team. Do not worry – Iboga does not condemn and it has no opinion. Iboga is there for you to give you insights and information – it will give you exactly what you need, providing solution.

At the end of the ceremony we close with a sacred prayer and then break our fast with a lovely meal of soups, fruits and drinks. All food served is vegetarian / vegan.

At each retreat, there are up to 4 participants at a time with each participant being monitored and guided through the ceremony 24/7. Participants are fully cared for in a kind, gentle, non-infringing and relaxed way.

  • •  We provide personalised attention to cover your needs and understand your case. You will be informed of the dose and form of Iboga you will receive and we shall endeavour to clarify any questions you might have.
  • •  You will be assisted and monitored at all times by care providers with extensive experience on administering plant medicines.
  • •  Not only will you be in a caring, safe and loving environment but also in a beautiful and peaceful setting.
  • •  Total privacy and confidentiality of all information and records regarding your care.

Preparation for an Iboga retreat starts with pre-care which is done in association with our professional team. Once your questionnaire has been received and vetted by our professionals you will need to submit the following medical tests.

* an ECG and your cardiologists interpretation of it (to test if your heart is healthy enough for the experience).

* blood tests to assess general health and to identify any heart or liver problems. 

The tests are compulsory and no place will be offered without these tests being submitted. Our doctors will assess the results and confirm if you may be offered a place.

Two weeks prior to the retreat each participant is required to prepare with a specific diet as physically you need to prepare your body for the experience. This includes not eating fried foods, eating only fresh fruits and raw or boiled vegetables, drinking only juice, water or tea, no alcohol or coffee.

5 to 7 days before attending take Vitamin B complex.

It is also good to take increased doses of Vitamin C – at least 2000mg per day for at least 5 to 7 days. It is important that you have a positive mental attitude. Part of the pre-care is for us to ensure you are well prepared for the experience. If we feel you are not ready for a treatment then we will delay your attendance until you are.

It is also important not to arrive at a retreat with expectations. Nothing can really prepare you for an experience with Iboga. However it is important to have a clear intention. This can be very simple.

     • Would Iboga help heal my addiction to…. tobacco, pot, sugar, etc.,

     • Would Iboga help clear me of negative thought patterns?

  •      • Would Iboga help me find the next step in life?

The environment (setting) is also critically important. A quiet, dark room and natural surroundings are important before, during and after the treatment as is the possibility to walk in nature when required. We provide you with the appropriate music played at specific times during your session. We monitor you throughout the entire time of the experience so you get all the care and support you need.

We currently cater for minor addictions – smoking, pot, food, social media, technology, pornography. We also cater for alcohol addiction.

We do not currently cater for people with heroin, methadone, cocaine and other opiate addictions.

Our main focus lies on offering a psycho-spiritual experience. We firmly believe in the benefits of this experience, and are fully committed to helping you heal your emotional, physical and spiritual being in order to free yourself from any past negative patterns and cravings. Therefore we strongly advise you to always seek professional help in any case of addictions.


According to a recent study* (2017) performed by E. Noller phD at MAPS (Multidisiplinary Association for Psychedelic Studies) the long-term efficacy of Ibogaine assisted therapy on opioid dependant subjects showed promising results. 12 months after the treatment, 75% of the tested subjects turned out to be negative. The results expressed in this study do not reflect the same results obtained in our organisation, and are solely for informational purposes.

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

  • Iboga’s success rate in the treatment of addictions depends on many factors:
  • • Determination/motivation of the patient
  • • Severity of the problem
  • • Treatment in a kind, caring and professional environment
  • • Patient’s willingness to follow the guidelines
  • Iboga can be a near-miraculous medicine which facilitates withdrawal-free detox and a craving free life. There have been many studies and they report that iboga’s success rate lie somewhere between 35-77%.

There are a number of exclusion criteria which can make a person unsuitable for Iboga treatment. Following those rules is extremely important. Not following them can have lethal consequences. Finding out whether Iboga is safe for you is a complex task which depends on several factors. It is up to your provider to make an informed assessment, based on your application form and your medical tests. There may be additional testing required for some participants. This is why your application form must be filled out accurately and honestly, to find out which tests may be necessary in your case and if your health history meets the treatments inclusion/exclusion criteria.

Here is a list of criteria in which presence we cannot provide Iboga for:

  • Certain Psychiatric Conditions
  • •  Schizophrenia
  • •  Bipolar disorder for which participant has been hospitalized or medicated
  • •  Depersonalization and/or Derealization Disorder
  • •  Cerebellar dysfunction
  • •  Epilepsy
  • •  Psychosis or acute confusional state
  • •  Organic brain disease
  • •  Dementia
  • Certain Pre-Existing Heart Conditions
  • •  Prolonged QTc Interval
  • •  History of heart failure, enlarged or hypertrophic heart
  • •  Active blood clots
  • •  Pulmonary embolism
  • •  Deep vein thrombosis
  • Certain Major Respiratory Conditions
  • •  Low oxygen levels and required steroid treatments lead to excessive risks.
  • •  Emphysema
  • •  Chronic Obstructive Pulmonary Disorder
  • •  Cystic Fibrosis
  • Severe or Chronic Gastrointestinal Issues
  • •  Bleeding ulcer
  • •  Leaky gut syndrome
  • Other Criteria
  • •  Abnormal blood test results
  • •  Impaired Kidney or Liver function
  • •  Active infection or abscess
  • •  Within 6 months of major surgeries
  • •  Pregnancy
  • •  If you are on Benzodiazepines

3-Day All Inclusive Programme – €1,000 per person (shared)

  • Full pre-care and preparation for the Iboga Ceremony
  • 1 Iboga Ceremony
  • 24hr Care & Support throughout the retreat
  • After-Care Program
  • Free Wi-Fi
  • Food and Accommodation – Organic Vegetarian/Vegan Meals
  • Airport Pick-up/Drop-off

There is an option, where available, to stay on with us after the retreat for further day at a cost of €100 per day.

Private retreat – Some people prefer privacy. It is possible to have a private iboga retreat. Please contact us for details.


Bwiti is a religion that is practiced by the Babongo Mitsogo and the people of Gabon, where it is one of the three official religions. Modern Bwiti is a syncretic, animistic religion where ancestor worship is mixed with Christianity. The use of Iboga, which is specially cultivated, brings spiritual enlightenment and connection with the world. The root bark has been used for thousands of years in ceremony. It heals, causes liquid complex beautiful views and very valuable insights. It’s a godsend.

Bwiti is still not recognized by the Catholic church, which to this day keeps opposing the growing movement of Bwiti. In 1960, the first President of Gabon, Leon M’ba, defended the Bwiti religion and the use of Iboga in the French colonial courts. The Ministers of Gabon declared the Tabernanthe Iboga as their national treasure in 2001. It is known that 4% of the population, including the president, use Iboga.


Iboga can be described as a “plant spirit”. Over thousands of Babongo and various Bantu tribes celebrate it, always with modesty and respect. It is a “spiritual” bath with the plants of the forest and provides insights. In a group ritual with dance, music and fire, many days are spent in reflection.


Bandzioku lost her husband in the jungle, when he went to pick fruit from a tree and fell. She could not find his body and returned to the village. According to tradition, she married the brother of her husband.

One day she went fishing, but in her net she found not only fish, but the bones of her husband as well.

She took the bones to the shore where they were taken by an animal. Bandzioku followed this animal to a cave. From the cave, the voices of the spirits of the dead called her: Bandzioku, would you like to see us? ”

When she said “yes”, the spirits instructed her to eat the root of a plant that was growing in a corner near the entrance of the cave. After she had eaten she could see spirits and talk with them. Among them was the spirit of her first husband. The spirits asked a sacrifice of her and she gave them her food supplies.


The next day she brought new supplies and went back to the cave to sacrifice them. She repeated this for several days. One day, her husband became suspicious and decided to follow her.

When she arrived at the cave, the spirits said “Muma, Muma” pointing out that an uninitiated person was present. Bandzioku thought she was alone, then turned and saw her second husband.

He asked her who she was talking to. After she had told him everything, he also wanted to eat the root. She gave it to him and then he could also talk to the spirits.

The spirits also asked him for a sacrifice, he gave them the little he had, but this was rejected by the spirits. The spirits wanted him to sacrifice Bandzioku. She was killed and sacrificed. Her husband took the plant and returned back to his village. He built the first Bwiti temple.

There is a lot written about Iboga. Please find a list below of suggested literature.


 Iboga: The Visionary Root of African Shamanism – Vincent Ravalec, Mallendi, Agnes Paicheler

Breaking Open the Head by Daniel Pinchbeck – includes one of eight parts on iboga, well described.

Ibogaine Explained – Peter Frank and Eric Taub

Healing with Iboga by Holly Stein, a 20-page booklet

Heart Medicine: A True Love Story – Elizabeth Bast Bast is a flamboyant story of a couple seeking healing when the man relapses into a heroin addiction.

Rehab Doesn’t Work, Ibogaine Does by Willers T Darenvogt.

The Ibogaine Story – Paul de Rienzo and Dana Beal

Iboga Visions – Jim Macgregor

Auler A. Climbing the Holy Mountain of Recovery. Trafford. 2015.

Sazy L. Bokayé: Bwiti Ceremony. Blurb. 2016.

Other Literature

 Baillon. I. Alkaloids Constituents of seeds of Tabernanthe Iboga

Baill Goutarel, R.; Poisson, J.; Croquelois, G.; Rolland, Y.; Miet, C. (Elsevier, 1974-09) Alkaloids from Apocynaceae II. Ibogaline, A New Alkaloid From Tabernanthe Iboga 

Neuss, Norbert (ACS (American Chemical Society), 1959-12) The total synthesis of dl-ibogamine   

Sallay, Stephen I. (American Chemical Society, 1967-12-06) Extraction Studies of Tabernanthe Iboga and Voacanga Africana  

Jenks, Christopher W. (Taylor and Francis Ltd, 2002) Process for the manufacture of indoles and products obtained thereby

Taylor, William Irving (U.S. Patent Office, 1959-03-10) Biogenesis of Strychnos, Aspidosperma, and Iboga alkaloids. The structure and reactions of preakuammicine. 

Scott, A. I.; Qureshi, A. A. (American Chemical Society, 1969) 13C-NMR. Spectroscopy of Naturally Occurring Substances. XLV. Iboga Alkaloids 1)

Wenkert, Ernest; Cochran, David W.; Gottlieb, Hugo E.; Hagaman, Edward W. (Verlag Helvetica Chimica Acta, 1976-11-03) Contributions to the Chemistry of Indole, VII. Syntheses in the Iboga-Series, III. Ibogamine, Ibogaine, and Epiibogamine

Rosenmund, Peter; Haase, Wolfgang H.; Bauer, Juergen; Frische, Rainer (Wiley-VCH (Germany), 1975-06) The psychic effect of ibogaline hydrochloride (alkaloid from Tabernanthe iboga Baill)

Von Schmid, P. B. (Editio Cantor, 1967-04) III. Ibogaine, Tabernanthine, Voacangine-From Eboka To Sananho

Ott, Jonathan (Natural Products Co., Kennewick, WA, 1973)

About Ibolutein

Goutarel, M.; Janot, M.-M.; Mathys, F.; Prelog, V. (Verlag Helvetica Chimica Acta, 1956) Long-QT Syndrome Induced by the Antiaddiction Drug Ibogaine

Hoelen, D. W. M.; Spiering, W.; Valk, G. D. (Massachusetts Medical Society, 2009-01-15) Tabernanthine, ibogaine containing analgesic compositions.

Schneider, Jurg Adolf. (U.S. Patent Office, 1957-12-24) Addiction Treatment Strives for Legitimacy

Vastag, Brian (American Medical Association, 2002-12-25) Derivatives of the ibogaine alkaloids

Janot, Maurice-Marie; Goutarel, Robert (U.S. Patent Office, 1957-11-19) PHARMACODYNAMICS. Difference between the physiological action of ibogaine and that of cocaine. Communication from Mr. Raymond-Hamet, presented by Mr. Paul Portier.

Hamet, Raymond (Masson, Paris, 1940) Alkaloids From Voacanga schweinfurthii var. puberula

Richard, B.; Delaude, C.; Massiot, G.; Le Men-Olivier, L. (ACS Publications, 1983-03) Alkaloids of Pandaca species

Lévy, M. C.; Debray, M. -M.; Le Men-Olivier, L.; Le Men, J. (Elsevier Science Ltd., 1975-02) Alkaloids of Pandaca ochrascens

Panas, J. M.; Richard, B.; Sigaut, C.; Debray, M.-M.; Le Men-Olivier, L.; Le Men, J. (Elsevier, 1974-09) Anti-HIV-1 activity of the Iboga alkaloid congener 18-methoxycoronaridine

SILVA, Edinete M.; CIRNE-SANTOS, Claudio C.; FRUGULHETTI, Izabel C. P. P.; GALVAO-CASTRO, Bernardo; SARAIVA, Elvira M. B.; KUEHNE, Martin E.; BOU-HABIB, Dumith Chequer (Thieme, Stuttgart, ALLEMAGNE, 2004) Previous Page

Solution-Phase Parallel Synthesis of N,6-Disubstituted Isoquinuclidines as Ibogaine Analogs

Levi, M. S.; Khan, M. O. F.; Borne, R. F. (Bentham Science Publishers, 2005) Gas chromatographic determination of ibogaine in biological fluids

Cartoni, G. Paolo; Giarusso, Alberto (Elsevier B.V., 1972-08-23) Alkaloids in Tabernaemontana species, XII. Investigation of the alkaloids from Tabernaemontana olivacea – condylocarpine-N-oxide, a new alkaloid from T. olivacea

Achenbach, Hans; Raffelsberger, Bernd (1980) Alkaloids in Tabernaemontana species, XI. Investigation of the alkaloids from Tabernaemontana quadrangularis – (20R)-20-hydroxyibogamine, a new alkaloid from T. quadrangularis

Achenbach, Hans; Raffelsberger, Bernd (Elsevier Science, 1980) Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction

Maas, U.; Strubelt, S. (Elsevier, 2006) Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures

Mash, Deborah C. (2001) Pharmacokinetic studies on structure-activity relationship of tremor-producing harmala and iboga alkaloids.

Singbartl, G.; Zetler, G.; Schlosser, Lucie (Springer Berlin / Heidelberg I, 1972) Indole alkaloids and terpenoids from Tabernaemontana markgrafiana

Nielsen, Helene B.; Hazell, Alan; Hazell, Rita; Ghia, Felipe; Torssell, Kurt B. G. (Elsevier Ltd., 1994-12) The alkaloids of Peschiera lundii (D. C.) Miers. Isolation and structure elucidation of voacristine pseudoindoxyl and iboxygaine hydroxyindolenine.

Hwang, Bruce; Weisbach, Jerry A.; Douglas, Bryce; Raffauf, Robert F.; Cava, Michael P.; Bessho, Kiyoshi (American Chemical Society, 1969-02) Central effects of voacangine, voacamine, voacamidine, voacorine, and ibogaine

Zetler, G.; Unna, K. R. (Springer Berlin / Heidelberg, 1959-01)

Mechanisms of antiaddictive actions of ibogaine

Glick, STANLEY D.; Maisonneuve, ISABELLE M. (New York Academy of Sciences, 1998-05-30) Synthesis of analogs of ibogaine.

Warthen, John David Jr. (ProQuest UMI Dissertation Publishing, 1966) The actions of 11 indole-alkaloids on the guinea pig heart in vivo and in vitro, compared with those of 2 synthetic azepinoindoles, quinidine and quindonium.

Zetler, G.; Lenschow, E.; Prenger-Berninghoff, W. (Springer Berlin / Heidelberg, 1968-01) Ibogaine and the dopaminergic response to nicotine.

Maisonneuve, I. M.; Mann, G. L.; Deibel, C. R.; Glick, S. D. (Springer-Verlag, 1997-02) The ibogaine medical subculture

Alper, Kenneth R.; Lotsof, Howard S.; Kaplan, Charles D. (Elsevier Sequoia, 2008-01-04) On ibogine, the active ingredient of a plant of the genus Tabernaemontana, originating in the Congo.

Haller, A.; Heckel, Ed (French Academy of Sciences, 1901) 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats

Glick, Stanley D.; Ramirez, Ruby L.; Livi, Jacklyn M.; Maisonneuve, Isabelle M. (Elsevier B.V., 2006-03-24) Plant derivatives in the treatment of alcohol dependency.

Rezvani, Amir H.; Overstreet, David H.; Perfumi, Marina; Massi, Maurizio (Elsevier, 2003-06) Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors

Layer, Richard T.; Skolnick, Phil; Bertha, Craig M.; Bandarage, Upul K.; Kuehne, Martin E.; Popik, Piotr (Elsevier Science, 1996-08-08)

Fernandez, Bwiti: Een etnografie van de Godsdienstige Verbeelding in Afrika

Goutarel, Gollnhofer en Sillans, Farmacodynamica en Therapeutische Toepassingen van Iboga en Ibogaine

Psychotherapeutische mogelijkheden van nieuwe Fantasy-doping – Klinische Toxicologie (Naranjo, C. 1969)

A Preliminary Manual for Ibogaine Therapy, by Howard Lotsof and Boaz Wachtel

An Introduction to Ibogaine (Treatment Section), by Nick Sandberg

Ibogaine in the Treatment of Chemical Dependence Disorders: Clinical Perspectives, by Howard Lotsof

An Ibogaine Treatment Protocol  by Geerte of INTASH, (International Addict Self-Help)

Ibogaine Treatment Notes from Brian Mariano in the Czech Republic

Ott, Jonathan (Natural Products Co., Kennewick, WA, 1973) III. Ibogaine,Tabernanthine, Voacangine-From Eboka To Sananho

Ott, Jonathan (Natural Products Co., Kennewick, WA, 1973) Study of iboga (Tabernanthe iboga H. Bn.).

Delourme-Houde, M. Jean (Elsevier, 1946) The Iboga and Voacanga alkaloids.

Taylor, W. I. (Academic Press, New York, 1965) Two New Pharmacological Properties of Ibogaine Common to This Alkaloid and to Cocaine

Hamet, Raymond (Masson, Paris, 1940-03-16) 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats

Glick, S. D.; Kuehne, M. E.; Maisonneuve, I. M.; Bandarage, U. K.; Molinari, H. H. (Elsevier, 1996) Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids

Zetler, G.; Singbartl, G.; Schlosser, Lucie (Karger, 1972) The Total Synthesis of Iboga Alkaloids

Buchi, G.; Coffen, D. L; Kocsis, Karoly; Sonnet, P. E.; Ziegler, Frederick (American Chemical Society, 1966) Non-amphetaminic central stimulation by alkaloids from the ibogaine and vobasine series

Bert, Maryse; Marcy, Rene; Quermonne, Marie-Anne; Cotelle, Michel; Koch, Michel (George Thieme, 1988-06) Alkaloids of Tabernaemontana wallichiana

Talapatra, S.K.; Sen Gupta, S.; Bhattacharya, M.; Talapatra, B. (National Institute of Science Communication and Information Resources, 1976)

Pharmacology of Ibogaine and Ibogaine-related Alkaloids, Piotr Popik and Phil Skolnick, (1999).

Luciano, DJ. (1998). Observations on treatment with Ibogaine. (American Journal of Addictions 7, 89-90).

Alper, KR, Lotsof, HS, Frencken, GMN, Luciano, DJ, and Bastiaans, J (1999). Treatment of Acute Opioid Withdrawal Syndrome with Ibogaine. (American Journal of Addictions 8, 234-242).

Luciano DJ, Della Sera, EA, and Jethmal, EG (2000). Neurologic, electroencephalographic and general medical observations in subjects administered ibogaine. (Bulletin of Multidisciplinary Association for Psychedelic Studies 9, 27-30).

Mash DC, Kovera CA, Pablo J, Tyndale RF, Ervin FD, Williams IC, Singleton EG, Mayor M (2000). Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. (Ann N Y Acad Sci 2000; 914:394-401).

Fernandez, J. W., Bwiti: An Ethnography of Religious Imagination in Africa. Princeton University Press (1982)

Glick, S.D. et al., Effects and Aftereffects of Ibogaine on Morphine Self-administration in Rats. Eur. J. Pharmacol. 195:341-345 (1991)

Cappendijk, S.L.T. et al., Inhibitory Effects of Ibogaine on Cocaine Self-administration in Rats. Eur. J. Pharmacol. 241:261-265 (1993)

Rezvani, A.H. et al., Attenuation of Alcohol Intake by Ibogaine in Three Strains of Alcohol-preferring Rats. Pharmacology, Biochemistry and Behavior 52(2):615-620 (1995)

Alper, K.R. et al., The Ibogaine Medical subculture, Journal of Ethnopharmacology, 115: 9-24 (2008)

Jeffrey D. Kamlet, MD, FASAM, DABAM, Fellow, American Society of Addiction Medicine. USA. Dr. Kamlet treated over 400 patients as a clinical study sample on the island of St. Kitts to FDA standards.

J. W. Fernandez. Bwiti: An Ethnography of the Religious Imagination of Africa. Princeton University Press, Princeton, NJ, (1982).

D. F. Dickel; C. L. Holden; R. C. Maxfield; L. E. Paszek and W. I. Taylor. The alkaloids of Tabernanthe iboga. Part III. Isolation studies. Journal of the American Chemical Society, (1958), 80, 123-125.

R. E. Schultes and A. Hofmann. The Botany and Chemistry of Hallucinogens, 2nd ed. C. C. Thomas, Springfield, IL, (1980), 233-240.

C. Naranjo. The Healing Journey. Pantheon Books, Div. Random House, NY, (1973), 174-228.

P. Popik; R. T. Layer and P. Skolnick. “100 Years of ibogaine – neurochemical and pharmacological actions of a putative anti-addictive drug.” Pharmacological Reviews, (1995), 47(2), 235-253. S. G. Sheppard. “A preliminary investigation of ibogaine: case reports and recommendations for further study.” Journal of Substance Abuse Treatment, (1994), 11(4), 379-385.

S. Nadis. “The mystery of ibogaine: can an African psychedelic cure addiction?” Omni, (July 1993), 15(9), 14.

H. S. Lotsof. “Rapid method for interrupting the narcotic addiction syndrome.” United States patent, (1985), 4,499,096; Cocaine and amphetamine: US patent, (1986), 4,587,243; Alcohol: US patent, (1989), 4,857,523; Nicotine: US patent, (1991), 5,026,697; Poly-drug dependency: US patent, (1992), 5,152,994.

Howard Lotsof, personal communication. Also see http://www.ibogaine.org

M-M. Janot and R. Goutarel. “Derivatives of the ibogaine alkaloids.” United States patent, (November 19, 1957), 2,813,873.

B. M. Trost; S. A. Godleski and J. P. Genet. “A total synthesis of racemic and optically active ibogamine. Utilization and mechanism of a new silver ion assisted palladium catalyzed cyclization.” Journal of the American Chemical Society, (1978), 100(12), 3930-3931.

A. Hofmann and F. Troxler. “Esters of Indoles.” United States patent, (January 29, 1963), 3,075,992. C. C. Keller. “Neue Studien uber Secale Cornutum, Ergotinin, Cornutin, Spasmotin.” Schweizerische Wochenschrift fur Chemie und Pharmacie, (1896), 34, 65-74.

D. W. Thomas and K. Biemann. “The alkaloids of Voacanga africana.” Lloydia, (1968), 31(1), 1-8.

Schenberg, E. E., de Castro Comis, M. A., Rasmussen Chaves, B. & da Silveira, D. X. (2014). Treating drug dependence with the aid of ibogaine: A retrospective study. Journal of Psychopharmacology,28(11), 993-1000.

Candida Study

Tang, B. Q., Wang, W. J., Huang, X. J., Li, G. Q., Wang, L., Jiang, R. W., … & Ye, W. C. (2014). Iboga-Type Alkaloids from Ervatamia officinalis. Journal of natural products, 77(8), 1839-1846. Iboga-Type Alkaloids from Ervatamia officinalis

Chen A, Ashburn MA. (2015) Cardiac Effects of Opioid Therapy. Pain Med. 16 Suppl 1: S27-31.

[6] Belgers, M., Leenaars, M., Homberg, J. R., Ritskes-Hoitinga, M., Schellekens, A. F., & Hooijmans, C. R. (2016). Ibogaine and addiction in the animal model, a systematic review and meta-analysis.Translational Psychiatry, 6(5), e826.

Dos Santos, R. G., Bouso, J. C., Hallak, J. E. C. (2017). The antiaddictive effects of ibogaine: A systematic literature review of human Studies. 1(1): 20–28. Journal of Psychedelic Studies.

Wilkins, C., dos Santos, R. G., Solá, J., Aixalá, M., Cura, P., Moreno, E., Alcázar-Córcoles, M. A., Hallak, J. E. C., Bouso, J. C. (2017). Detoxification from methadone using low, repeated, and increasing doses of ibogaine: A case report. Journal of Psychedelic Studies. 1(1), pp. 29–34.

Schep, L. J., Slaughter, R. J., Galea, S., & Newcombe, D. (2016). Ibogaine for treating drug dependence. What is a safe dose? Drug and Alcohol Dependence, 166, 1–5.

Dos Santos, R. G., Bouso, J. C., Hallak, J. E. C. (2017). The antiaddictive effects of ibogaine: A systematic literature review of human Studies. 1(1): 20–28. Journal of Psychedelic Studies.

Brown, Thomas Kingsley, Kenneth Alper. (2017). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse, 1-13.

Noller, Geffrey E., Chris M. Frampton, and Berra Yazar-Klosinski. (2017) Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse. 1-10.

Academic Articles

Dickinson JD. Iboga Root: Dynamics of Iboga’s African Origins and Modern Medical Use. HerbalGram;American Botanical Council. Spring 2016;109. HerbalGram Online

Mash DC, Ameer B, Prou D, Howes JF, Maillet EL. Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents. Journal of Psychopharmacology.April 4, 2016. PubMe